Cluster Headache Market
The Cluster Headache market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Cluster Headache symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Cluster Headache symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.
Cluster Headache Market Outlook
The Cluster Headache market outlook helps build a detailed comprehension of the historical, current, and forecasted Cluster Headache market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Cluster Headache market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Cluster Headache market in 7MM is expected to grow in the study period 2018–2030.
As per DelveInsight’s analysis, the number of patients suffering from the episodic form is much higher than those suffering from the chronic form. In the US, in 2018, there were 157,040 cases of the episodic form of CH and 39,260 cases of the chronic form of CH. These are projected to increase to 170,448 and 42,612 cases for episodic and chronic form, respectively. The treatment for cluster headache can be divided into three treatment phases: a fast-acting abortive treatment, preventive drugs, and transitional treatment to bridge the period between patients starting preventive drug dosages and the drugs asserting an effect. The acute treatment includes Triptans, High-flow oxygen, Somatostatin, and Somatostatin Analogues, among others. Prophylactic treatment drugs of the first choice are verapamil, lithium, and topiramate.
Key Findings
This section includes a glimpse of the Cluster Headache market in the 7MM.
The market size of Cluster Headache in the seven major markets was USD 741.8 million in 2020.
Cluster Headache Pipeline Development Activities
The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Cluster Headache’s key players involved in developing targeted therapeutics.
Major players include Lundbeck Seattle BioPharmaceuticals and Winston Laboratories.
Request for sample pages @ Cluster Headache market
Table of contents
1. Key Insights
2. Report Introduction
3. Cluster Headache Market Overview at a Glance
3.1. Market Share (%) Distribution of Cluster Headache in 2018
3.2. Market Share (%) Distribution of Cluster Headache in 2030
4. Executive Summary of Cluster Headache
5. Disease Background and Overview
5.1. Introduction
5.2. Classification of Cluster Headache
5.3. Clinical Characteristics
5.4. Comorbidities associated with Cluster Headache
5.5. Cluster Headache versus Migraine
5.6. Risk Factors associated with Cluster Headache
5.7. Pathophysiology
5.7.1. Trigeminovascular System
5.7.2. Parasympathetic Activation
5.7.3. Hypothalamus Activation
5.8. Diagnosis
5.8.1. Differential Diagnosis
5.9. Treatment
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. 7MM Total Diagnosed Incident Population of Cluster Headache
6.3. Epidemiology of Cluster Headache
6.4. The United States
6.4.1. Prevalence of Cluster Headache in the United States
6.4.2. Diagnosed cases of Cluster Headache in the United States
6.4.3. Type-specific cases of Cluster Headache in the United States
6.4.4. Gender-specific cases of Cluster Headache in the United States
6.4.5. Age-specific cases of Cluster Headache in the United States
6.5. EU5
6.5.1. Germany
6.5.1.1. Prevalence of Cluster Headache in Germany
6.5.1.2. Diagnosed cases of Cluster Headache in Germany
6.5.1.3. Type-specific cases of Cluster Headache in Germany
6.5.1.4. Gender-specific cases of Cluster Headache in Germany
6.5.1.5. Age-specific cases of Cluster Headache in Germany
6.5.2. France
6.5.2.1. Prevalence of Cluster Headache in France
6.5.2.2. Diagnosed cases of Cluster Headache in France
6.5.2.3. Type-specific cases of Cluster Headache in France
6.5.2.4. Gender-specific cases of Cluster Headache in France
6.5.2.5. Age-specific cases of Cluster Headache in France
6.5.3. Italy
6.5.3.1. Prevalence of Cluster Headache in Italy
6.5.3.2. Diagnosed cases of Cluster Headache in Italy
6.5.3.3. Type-specific cases of Cluster Headache in Italy
6.5.3.4. Gender-specific cases of Cluster Headache in Italy
6.5.3.5. Age-specific cases of Cluster Headache in Italy
6.5.4. Spain
6.5.4.1. Prevalence of Cluster Headache in Spain
6.5.4.2. Diagnosed cases of Cluster Headache in Spain
6.5.4.3. Type-specific cases of Cluster Headache in Spain
6.5.4.4. Gender-specific cases of Cluster Headache in Spain
6.5.4.5. Age-specific cases of Cluster Headache in Spain
6.5.5. United Kingdom
6.5.5.1. Prevalence of Cluster Headache in the United Kingdom
6.5.5.2. Diagnosed cases of Cluster Headache in the United Kingdom
6.5.5.3. Type-specific cases of Cluster Headache in the United Kingdom
6.5.5.4. Gender-specific cases of Cluster Headache in the United Kingdom
6.5.5.5. Age-specific cases of Cluster Headache in the United Kingdom
6.6. Japan
6.6.1. Prevalence of Cluster Headache in Japan
6.6.2. Diagnosed cases of Cluster Headache in Japan
6.6.3. Type-specific cases of Cluster Headache in Japan
6.6.4. Gender-specific cases of Cluster Headache in Japan
6.6.5. Age-specific Cases of Cluster Headache in Japan
7. Organizations contributing towards Cluster Headache
8. Patient Journey
9. Case Reports
10 Marketed Products
10.1. EMGALITY (Galcanezumab-gnlm): Eli Lilly and Company
10.1.1. Product Description
10.1.2. Mechanism of action
10.1.3. Regulatory Milestones
10.1.4. Safety and Efficacy of EMGALITY
10.1.5. Product Profile
11. Emerging Therapies
11.1. Key Cross Competition
11.2. VYEPTI (Eptinezumab): Lundbeck Seattle BioPharmaceutical
11.2.1. Drug Description
11.2.2. Regulatory Milestones
11.2.3. Clinical Development
11.2.4. Clinical Trials Information
11.2.5. Safety and Efficacy
11.2.6. Product Profile
11.3. Civamide (Zucapsaicin): Winston Laboratories
11.3.1. Drug Description
11.3.2. Regulatory Milestones
11.3.3. Clinical Development
11.3.4. Clinical Trials Information
11.3.5. Safety and Efficacy
11.3.6. Product Profile
12. Other Drugs under Development
12.1. Zolmitriptan transdermal (C213): Zosano Pharma
12.1.1. Drug Description
12.1.2. Clinical Development
12.1.3. Clinical Trials Information
12.1.4. Product Profile
13. Cluster Headache: Seven Major Market Analysis
13.1. Key Findings
13.2. Market Size of Cluster Headache in 7MM
13.3. Market Outlook
13.4. United States Market Size
13.1.1. Total Market Size of Cluster Headache in the United States
13.1.2. Market Size of Cluster Headache by Therapies in the United States
13.5. EU-5 Market Size
13.5.1. Germany
13.5.1.1. Total Market Size of Cluster Headache in Germany
13.5.1.2. Market Size of Cluster Headache by Therapies in Germany
13.5.2. France
13.5.2.1. Total Market Size of Cluster Headache in France
13.5.2.2. Market Size of Cluster Headache by Therapies in France
13.5.3. Italy
13.5.3.1. Total Market Size of Cluster Headache in Italy
13.5.3.2. Market Size of Cluster Headache by Therapies in Italy
13.5.4. Spain
13.5.4.1. Total Market Size of Cluster Headache in Spain
13.5.4.2. Market Size of Cluster Headache by Therapies in Spain
13.5.5. United Kingdom
13.5.5.1. Total Market Size of Cluster Headache in the United Kingdom
13.5.5.2. Market Size of Cluster Headache by Therapies in the United Kingdom
13.6. Japan
13.6.1. Total Market size of Cluster Headache in Japan
13.6.2. Market Size of Cluster Headache by Therapies in Japan
14. KOL Views
15. Market Drivers
16. Market Barriers
17. SWOT Analysis
18. Unmet Needs
19. Market Access
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/